GW Pharmaceuticals Plc (GWPH)

164.98
5.12 3.01
NASDAQ : Health Technology
Prev Close 170.10
Open 170.01
Day Low/High 163.00 / 172.50
52 Wk Low/High 96.42 / 174.50
Volume 974.41K
Avg Volume 411.40K
Exchange NASDAQ
Shares Outstanding 28.20M
Market Cap 4.80B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
GW Pharmaceuticals Reaches Analyst Target Price

GW Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of GW Pharmaceuticals plc have crossed above the average analyst 12-month target price of $168.88, changing hands for $170.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

What is THC? Experts Weigh in on Benefits and Effects

What is THC? Experts Weigh in on Benefits and Effects

THC is the psychoactive ingredient in marijuana that produces the feeling of being high. But, THC also has other applications that include health benefits and some side effects.

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

Jim Cramer weighs in on DocuSign, DexCom, Skechers USA, Campbell Soup, Evolus, Zscaler, Lockheed Martin and more.

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.

Seven U.S. Stocks Offering Cannabis Exposure

Seven U.S. Stocks Offering Cannabis Exposure

While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

It's important to know the difference between broken stocks and broken companies.

Snap, Costco, Seagate Technology: 'Mad Money' Lightning Round

Snap, Costco, Seagate Technology: 'Mad Money' Lightning Round

Jim Cramer shines a spotlight on Snap, Costco, Seagate Technology, GW Pharmaceuticals, Danaher, General Mills and more.

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

We have a wall of worry to overcome, but it's important to hear the other side of the trade, says Jim Cramer. Take Apple and Facebook, for example.

Cannabis Industry Sits on Precipice of Major Expansion

Cannabis Industry Sits on Precipice of Major Expansion

A string of good news for the cannabis sector may prompt institutional investors to get into the game, but watch valuations increase.

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Jim Cramer says analysts and trade woes put a damper on buying ahead of the weekend. So let's get the game plan for next week.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at American Electric Power, Fifth Third Bancorp, Applied Materials, EPR Properties, GW Pharmaceuticals and Longfin.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.

TheStreet Quant Rating: D (Sell)